CTI BioPharma Corp. (CTIC): Price and Financial Metrics


CTI BioPharma Corp. (CTIC): $5.63

-0.12 (-2.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CTIC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CTIC POWR Grades

  • Growth is the dimension where CTIC ranks best; there it ranks ahead of 82.72% of US stocks.
  • CTIC's strongest trending metric is Value; it's been moving up over the last 177 days.
  • CTIC's current lowest rank is in the Stability metric (where it is better than 2.44% of US stocks).

CTIC Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CTIC is -1.95 -- better than just 4.29% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -9.98 for CTI BIOPHARMA CORP; that's greater than it is for only 2.11% of US stocks.
  • As for revenue growth, note that CTIC's revenue has grown 1,332.03% over the past 12 months; that beats the revenue growth of 99.21% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CTI BIOPHARMA CORP are NH, QMCO, DESP, AVID, and FCEL.
  • CTIC's SEC filings can be seen here. And to visit CTI BIOPHARMA CORP's official web site, go to www.ctibiopharma.com.

CTIC Valuation Summary

  • In comparison to the median Healthcare stock, CTIC's price/sales ratio is 914.29% higher, now standing at 21.3.
  • CTIC's price/sales ratio has moved up 3.5 over the prior 243 months.

Below are key valuation metrics over time for CTIC.

Stock Date P/S P/B P/E EV/EBIT
CTIC 2023-01-30 21.3 -41.5 -6.2 -7.7
CTIC 2023-01-27 22.1 -43.1 -6.5 -7.9
CTIC 2023-01-26 22.5 -43.9 -6.6 -8.1
CTIC 2023-01-25 23.2 -45.3 -6.8 -8.3
CTIC 2023-01-24 23.2 -45.2 -6.8 -8.3
CTIC 2023-01-23 22.9 -44.6 -6.7 -8.2

CTIC Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -104.79%.
  • Its 4 year net income to common stockholders growth rate is now at 44.92%.
  • Its 5 year net cashflow from operations growth rate is now at 44.15%.
CTIC's revenue has moved up $11,181,000 over the prior 67 months.

The table below shows CTIC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 32.865 -95.702 -112.322
2022-06-30 14.624 -100.74 -120.796
2022-03-31 2.295 -98.089 -117.817
2021-12-31 0 -84.889 -97.908
2021-09-30 0 -65.691 -76.122
2021-06-30 0 -56.566 -63.206

CTIC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTIC has a Quality Grade of C, ranking ahead of 52.35% of graded US stocks.
  • CTIC's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • AIM, RIGL, and ICCC are the stocks whose asset turnover ratios are most correlated with CTIC.

The table below shows CTIC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -73.017
2021-03-31 0.000 NA -20.791
2020-12-31 0.000 NA -14.733
2020-09-30 0.000 NA -12.206
2020-06-30 0.034 1 -14.511
2020-03-31 0.042 1 -4.357

CTIC Price Target

For more insight on analysts targets of CTIC, see our CTIC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.28 Average Broker Recommendation 1.33 (Strong Buy)

CTIC Stock Price Chart Interactive Chart >

Price chart for CTIC

CTIC Price/Volume Stats

Current price $5.63 52-week high $7.80
Prev. close $5.75 52-week low $1.82
Day low $5.61 Volume 2,369,400
Day high $5.77 Avg. volume 2,943,500
50-day MA $5.70 Dividend yield N/A
200-day MA $5.67 Market Cap 714.41M

CTI BioPharma Corp. (CTIC) Company Bio


CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company was founded in 1991 and is based in Seattle, Washington.


CTIC Latest News Stream


Event/Time News Detail
Loading, please wait...

CTIC Latest Social Stream


Loading social stream, please wait...

View Full CTIC Social Stream

Latest CTIC News From Around the Web

Below are the latest news stories about CTI BIOPHARMA CORP that investors may wish to consider to help them evaluate CTIC as an investment opportunity.

CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023:

Yahoo | February 2, 2023

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on January 23, 2023, in accordance

Yahoo | January 25, 2023

CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

Yahoo | January 5, 2023

Has CTI BioPharma (CTIC) Outpaced Other Medical Stocks This Year?

Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.

Yahoo | December 28, 2022

12 Best Multibagger Stocks to Buy Now

In this article, we discuss 12 best multibagger stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Multibagger Stocks to Buy Now. In this uncertain market backdrop, investors are focused on macroeconomic and geopolitical constraints and their potential effects on investment portfolios. Goldman Sachs believes the […]

Yahoo | December 13, 2022

Read More 'CTIC' Stories Here

CTIC Price Returns

1-mo 4.07%
3-mo 13.28%
6-mo -9.63%
1-year 177.34%
3-year 331.42%
5-year 99.65%
YTD -6.32%
2022 142.34%
2021 -22.98%
2020 103.80%
2019 116.44%
2018 -72.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7853 seconds.